FGFR4 Promotes Cancer Cell Resistance in Response to Chemotherapeutic Drugs

Use of an FGFR4 inhibitor for the manufacture of a medicament for increasing the efficacy of a therapy or/and agent against a hyperproliferative disorder.

Use of an FGFR4 inhibitor for the manufacture of a medicament for increasing the sensitivity of a hyperproliferative disorder against radiation and/or medicament treatment.

A pharmaceutical composition or kit comprising as active ingredients

• (a) an FGFR4 inhibitor, and
• (b) an agent for the prevention, alleviation or/and treatment of a hyperproliferative disorder, which is different from (a),
• optionally together with a pharmaceutically acceptable carrier, diluent or/and adjuvant.

A method for preventing, alleviating or/and treating of a hyperproliferative disorder comprising administrating an effective amount of an FGFR4 inhibitor in co-administration with a further therapeutic procedure or/and a further therapeutic agent for a subject in need thereof.

A method for the diagnosis of a hyperproliferative disorder, wherein a sample from a subject which may suffer from a hyperproliferative disorder is analysed for the expression of the FGFR4 gene.

A method for the diagnosis of a hyperproliferative disorder, wherein a sample from a subject which may suffer from a hyperproliferative disorder is analysed for the presence of polymorphisms in the FGFR4 gene.

A method for the diagnosis of a hyperproliferative disorder, wherein a sample from a subject which may suffer from a hyperproliferative disorder is analysed for the expression of the FGFR4 gene and for the presence of polymorphisms in the FGFR4 gene.

A screening method for identifying or/and characterizing a compound suitable for reducing the apoptosis resistance of a hyperproliferative disorder comprising determining, if the compound is an FGFR4 inhibitor.